Floatz logo

Glembatumumab Vedotin

Stage IV Uveal Melanoma AJCC v7

National Cancer Institute (NCI)antibody_drug_conjugatePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Stage IV Uveal Melanoma AJCC v7 cohort.

Asset / SponsorPhaseRating
Cediranib
Grupo Español Multidisciplinar de Melanoma
Phase 2BB

Same molecule, other indications

Glembatumumab Vedotin is also rated in:

triple-negative breast carcinomaDormant
BB
Indicative ·
66 / 100
View asset →
uveal melanomaDormant
B
Indicative ·
62 / 100
View asset →
melanomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →